Bystander suppression of type I diabetes by oral administration of glucagon
AssigneeAutoimmune, Inc.
InventorsHoward Weiner, Ariel Miller, Zhengyi Zhang, Ahmad Al-Sabbagh
Life of this patent
Estimating the term…
Abstract
Described are methods for treating or preventing type I diabetes and insulitis by oral administration of the bystander antigen glucagon. The methods involve oral administration of glucagon in an amounts that are effective to treat or prevent type I diabetes or insulitis.
Claims6
A method for suppressing an autoimmune response associated with an autoimmune disease in a human, the method comprising orally or enterally administering to said human an effective amount for abating said response of a composition comprising a bystander antigen, wherein said disease is Type I diabetes and said bystander antigen is glucagon.
A method for suppressing insulitis in a human, the method comprising orally or enterally administering to said human an amount of a bystander antigen effective to suppress insulitis wherein said bystander antigen is glucagon.
Dependencies are inferred from the claim text.